Azadrox (silver/urea)
Topical Gel In Packet (Ml)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Urea, at concentrations of 10-30%, promotes hydration of keratin and mild keratolysis in dry and hyperkeratotic skin.
Urea is used topically in the treatment of dry skin. At concentrations of 10-30%, urea promotes hydration of keratin and mild keratolysis in dry and hyperkeratotic skin. The drug increases the uptake of water by the stratum corneum, giving it a high water-binding capacity.
Topically applied urea may also have an antipruritic effect. At high concentrations (e.g., 40%), urea is a protein denaturant.
Generic name: silver/urea
Therapeutic class: Dermatological
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Azadrox
Indications
No indications are available for this drug.
Dosing
Urea is applied topically as a cream or lotion. The moisturizing effect of urea may be enhanced by applying the preparation to the skin while it is still moist after washing or bathing. Urea is applied topically to the affected area 1-3 times daily or as directed by a physician.
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
Topical Heavy Metals/Topical Collagenase; Papain
SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
MECHANISM OF ACTION: Heavy metal ions may inactivate collagenase(1) and papain(2-10).
CLINICAL EFFECTS: Application of heavy metal ions such as lead, mercury, and silver may inactivate collagenase(1) and papain,(2-8) limiting their effectiveness.
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: Avoid applying topical products that contain heavy metals such as lead, mercury, or silver to the same wound areas as collagenase(1) and papain.(2-10)
DISCUSSION: The enzymatic activity of collagenase is adversely affected by heavy metal ions such as mercury and silver, which are used in some antiseptics.(1) Papain may be inactivated by heavy metal ions such as lead, mercury, and silver.(2-10)
Topical Silver/Topical Sodium Sulfacetamide
SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
MECHANISM OF ACTION: Topical sodium sulfacetamide and topical silver are physically incompatible.(1,2)
CLINICAL EFFECTS: Concurrent application of topical sodium sulfacetamide and topical silver preparations may result in decreased clinical effectiveness of the products.(1,2)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: Avoid using topical silver preparations on the same location as topical sodium sulfacetamide products.(1,2)
DISCUSSION: Topical sodium sulfacetamide and topical silver are physically incompatible.(1,2)
Moderate Interaction: Assess the risk to the patient and take action as needed.
Antimicrobial Topicals/Keratinocyte-Fibroblast Skin Tissue
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: Antimicrobial topicals or dressings containing chlorhexidine, mafenide, or silver may decrease the viability of keratinocytes and fibroblasts used for wound healing in skin tissue replacement products.
CLINICAL EFFECTS: The use of antimicrobial topicals or dressings containing chlorhexidine, mafenide, or silver may disrupt the integrity of keratinocyte human skin substitutes and decrease the viability of keratinocytes and fibroblasts.
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: The use of antimicrobial topicals or dressings containing chlorhexidine, mafenide, or silver is not recommended.
DISCUSSION: Mafenide acetate has been shown to reduce keratinocyte viability and disrupt the integrity of tissue-engineered human skin substitutes. In vitro data suggest silver may decrease the viability of keratinocytes and human dermal fibroblasts. Chlorhexidine has been shown to be toxic to keratinocytes and human dermal fibroblasts.(1)
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
- No disease contraindications
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
More Frequent
- Pruritus of skin
- Skin irritation
- Stinging of skin
Precautions
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.